NASDAQ:SLN Silence Therapeutics (SLN) Stock Price, News & Analysis $6.20 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$6.12 -0.08 (-1.21%) As of 05/22/2026 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Silence Therapeutics Stock (NASDAQ:SLN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Silence Therapeutics alerts:Sign Up Key Stats Today's Range$6.20▼$6.7350-Day Range$4.93▼$7.9752-Week Range$4.19▼$8.40Volume258,020 shsAverage Volume246,811 shsMarket Capitalization$292.89 millionP/E RatioN/ADividend YieldN/APrice Target$55.00Consensus RatingModerate Buy Company Overview Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities. The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism. Both programs have advanced through early clinical stages, generating proof-of-concept data. Silence also maintains a portfolio of preclinical research programs targeting liver-related diseases, while exploring strategic collaborations to broaden the reach of its RNAi platform across multiple therapeutic areas. Founded in the United Kingdom and headquartered in London, Silence Therapeutics operates research and development facilities in Europe and the United States. The company has navigated the evolving RNA therapeutics landscape since the early 2000s, transitioning from discovery research into clinical development. Under the leadership of Chief Executive Officer Eric M. Rose, Silence continues to advance its pipeline with the objective of delivering novel RNAi medicines to patients with high-unmet medical needs worldwide.AI Generated. May Contain Errors. Read More Silence Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreSLN MarketRank™: Silence Therapeutics scored higher than 45% of companies evaluated by MarketBeat, and ranked 585th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingSilence Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 3 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialSilence Therapeutics has a consensus price target of $55.00, representing about 787.1% upside from its current price of $6.20.Amount of Analyst CoverageSilence Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Silence Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Silence Therapeutics are expected to decrease in the coming year, from ($1.00) to ($1.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Silence Therapeutics is -3.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Silence Therapeutics is -3.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSilence Therapeutics has a P/B Ratio of 5.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Silence Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.71% of the float of Silence Therapeutics has been sold short.Short Interest Ratio / Days to CoverSilence Therapeutics has a short interest ratio ("days to cover") of 5.45.Change versus previous monthShort interest in Silence Therapeutics has recently increased by 3.91%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSilence Therapeutics does not currently pay a dividend.Dividend GrowthSilence Therapeutics does not have a long track record of dividend growth. News and Social Media1.3 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Silence Therapeutics this week, compared to 1 article on an average week.Search Interest2 people have searched for SLN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows1 people have added Silence Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Silence Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders3.00% of the stock of Silence Therapeutics is held by insiders.Percentage Held by Institutions98.73% of the stock of Silence Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Silence Therapeutics' insider trading history. Receive SLN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Silence Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SLN Stock News HeadlinesSilence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Average Recommendation of "Moderate Buy" from AnalystsMay 23 at 4:31 AM | americanbankingnews.comSilence Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:SLNMay 18, 2026 | benzinga.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason. | Banyan Hill Publishing (Ad)Silence Therapeutics highlights recent business achievements and reports first quarter 2026 financial resultsMay 7, 2026 | msn.comSilence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial ResultsMarch 5, 2026 | finance.yahoo.comSilence Therapeutics CEO Craig Tooman to end employmentDecember 15, 2025 | msn.comSilence Therapeutics Announces Leadership ChangesDecember 15, 2025 | businesswire.comSilence Therapeutics: Divesiran Targets High-Burden PVNovember 18, 2025 | seekingalpha.comSee More Headlines SLN Stock Analysis - Frequently Asked Questions How have SLN shares performed this year? Silence Therapeutics' stock was trading at $6.08 at the start of the year. Since then, SLN shares have increased by 2.0% and is now trading at $6.20. How were Silence Therapeutics' earnings last quarter? Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) issued its quarterly earnings data on Friday, May, 8th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.14. The company earned $0.42 million during the quarter, compared to analysts' expectations of $1.26 million. Silence Therapeutics had a negative net margin of 8,943.86% and a negative trailing twelve-month return on equity of 105.34%. Who are Silence Therapeutics' major shareholders? Silence Therapeutics' top institutional shareholders include SG Americas Securities LLC (0.61%), ADAR1 Capital Management LLC (0.36%), Hsbc Holdings PLC (0.26%) and Bank of America Corp DE (0.06%). How do I buy shares of Silence Therapeutics? Shares of SLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Silence Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Silence Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Jabil (JBL), e.l.f. Beauty (ELF), Disc Medicine (IRON) and Novo Nordisk A/S (NVO). Company Calendar Last Earnings5/08/2026Today5/24/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 SLN's financial health is in the Green zone, according to TradeSmith. SLN has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SLN CIK1479615 Webwww.silence-therapeutics.com Phone44-0-20-3457-6900FaxN/AEmployees100Year Founded1999Price Target and Rating Average Price Target for Silence Therapeutics$55.00 High Price Target$75.00 Low Price Target$35.00 Potential Upside/Downside+787.1%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$88.61 million Net Margins-8,943.86% Pretax Margin-8,942.55% Return on Equity-105.34% Return on Assets-52.79% Debt Debt-to-Equity RatioN/A Current Ratio9.83 Quick Ratio9.83 Sales & Book Value Annual Sales$560 thousand Price / Sales523.01 Cash FlowN/A Price / Cash FlowN/A Book Value$1.05 per share Price / Book5.90Miscellaneous Outstanding Shares47,240,000Free Float45,818,000Market Cap$292.89 million OptionableNot Optionable Beta1.52 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:SLN) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silence Therapeutics PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Silence Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
